Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study for the Evaluation of Molecular Markers Extracted From PRedittivI DNA of Clinical Outcomes and Response to Systemic Therapy in Patients With UROthelial Tumor.

NCT06863844 is registered in ClinicalTrials.gov with IRCCS Azienda Ospedaliero-Universitaria di Bologna as lead sponsor.

NCT NCT06863844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06863844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study for the Evaluation of Molecular Markers Extracted From PRedittivI DNA of Clinical Outcomes and Response to Systemic Therapy in Patients With UROthelial Tumor.
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Observational
Overall status
Recruiting
Start date
March 1, 2023
Completion date
March 31, 2025
Enrollment
210 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial neoplasm